Skip to main content
SpringerLink
Log in

Thrombolytic Treatment of Acute Pulmonary Embolism: Toward the End of a Long-Lasting Debate?

  • Conference paper
Venous Thromboembolism

  • 702 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dalen JE, Alpert JS, Hirsch J. Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated? Arch Intern Med 1997;157:2550–6.

    CAS  PubMed  Google Scholar 

  2. Dalen JE. The uncertain role of thrombolytic therapy in the treatment of pulmonary embolism. Arch Intern Med 2002;162:2521–3.

    PubMed  Google Scholar 

  3. Miller GA, Sutton GC, Kerr IH, et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Heart J 1971;33:616.

    CAS  PubMed  Google Scholar 

  4. Agnelli G, Becattini C, Kirschstein T. Thrombolysis vs. heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med 2002;162:2537–41.

    Article  CAS  PubMed  Google Scholar 

  5. Thabut G, Thabut D, Myers RP, et al. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol 2002;40:1660–7.

    Article  CAS  PubMed  Google Scholar 

  6. The urokinase pulmonary embolism trial. A national cooperative study. Circulation 1973;47:II1–108.

    Google Scholar 

  7. Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997;30:1165–71.

    Article  CAS  PubMed  Google Scholar 

  8. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993;341:507–11.

    CAS  PubMed  Google Scholar 

  9. Jerjes-Sanchez C, RamÍrez-Rivera A, de Lourdes G, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis 1995;2:227–9.

    CAS  PubMed  Google Scholar 

  10. Dalen JE, Banas JS Jr, Brooks HL, et al. Resolution rate of acute pulmonary embolism in man. N Engl J Med 1969;280:1194–9.

    CAS  PubMed  Google Scholar 

  11. Konstantinides S, Tiede N, Geibel A, et al. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol 1998;82:966–70.

    Article  CAS  PubMed  Google Scholar 

  12. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 1992;20:520–6.

    CAS  PubMed  Google Scholar 

  13. Goldhaber SZ, Vaughan DE, Markis JE, et al. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 1986;2:886–9.

    CAS  PubMed  Google Scholar 

  14. Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study. JAMA 1974;229:1606–13.

    Google Scholar 

  15. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990;98:1473–9.

    CAS  PubMed  Google Scholar 

  16. Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism [see comments]. J Am Coll Cardiol 1992;19:239–45.

    CAS  PubMed  Google Scholar 

  17. Sors H, Pacouret G, Azarian R, et al. Hemodynamic effects of bolus vs. 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994;106:712–17.

    CAS  PubMed  Google Scholar 

  18. Kanter DS, Mikkola KM, Patel SR, et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors [comment]. Chest 1997;111:1241–5.

    CAS  PubMed  Google Scholar 

  19. Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143–50.

    Article  CAS  PubMed  Google Scholar 

  20. Hamel E, Pacouret G, Vincentelli D, et al. Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest 2001;120:120–5.

    Article  CAS  PubMed  Google Scholar 

  21. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386–9.

    Article  CAS  PubMed  Google Scholar 

  22. Meyer G, Gisselbrecht M, Diehl JL, et al. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Am J Med 1998;105:472–7.

    Article  CAS  PubMed  Google Scholar 

  23. Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 1997;96:882–8.

    CAS  PubMed  Google Scholar 

  24. Hall RJ, Sutton GC, Kerr IH. Long-term prognosis of treated acute massive pulmonary embolism. Br Heart J 1977;39:1128–34.

    CAS  PubMed  Google Scholar 

  25. Gulba DC, Schmid C, Borst HG, et al. Medical compared with surgical treatment for massive pulmonary embolism. Lancet 1994;343:576–7.

    Article  CAS  PubMed  Google Scholar 

  26. Alpert JS, Smith R, Carlson J, et al. Mortality in patients treated for pulmonary embolism. JAMA 1976;236:1477–80.

    Article  CAS  PubMed  Google Scholar 

  27. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 1992;340:873–6.

    Google Scholar 

  28. Lualdi JC, Goldhaber SZ. Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications. Am Heart J 1995;130:1276–82.

    Article  CAS  PubMed  Google Scholar 

  29. Kasper W, Konstantinides S, Geibel A, et al. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997;77:346–9.

    CAS  PubMed  Google Scholar 

  30. Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000;101:2817–22.

    CAS  PubMed  Google Scholar 

  31. Janata K, Holzer M, Laggner AN, et al. Cardiac troponin T in the severity assessment of patients with pulmonary embolism: cohort study. BMJ 2003;326:312–13.

    PubMed  Google Scholar 

  32. Konstantinides S, Geibel A, Olschewski M, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002;106:1263–8.

    Article  CAS  PubMed  Google Scholar 

  33. Giannitsis E, Muller-Bardorff M, Kurowski V, et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000;102:211–17.

    CAS  PubMed  Google Scholar 

  34. Goldhaber SZ. Thrombolysis for pulmonary embolism. N Engl J Med 2002;347:1131–2.

    Article  PubMed  Google Scholar 

  35. Kucher N, Printzen G, Doernhoefer T, et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003;107:1576–8.

    PubMed  Google Scholar 

  36. Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonay embolism. Br Med J 1974;1:343–7.

    CAS  PubMed  Google Scholar 

  37. Ly B, Arnesen H, Eie H, et al. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978;203:465–70.

    CAS  PubMed  Google Scholar 

  38. Marini C, Di Ricco G, Rossi G, et al. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988;54:162–73.

    CAS  PubMed  Google Scholar 

  39. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. Chest 1990;97:528–33.

    Google Scholar 

  40. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs. conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Chest 1994;106:718–24.

    CAS  PubMed  Google Scholar 

  41. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 1992;20:24–30.

    Google Scholar 

  42. Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988;2:293–8.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology and Pulmonary Medicine, Georg August University, Robert Koch Strasse 40, D-37075, Goettingen, Germany

    Stavros Konstantinides

Authors
  1. Stavros Konstantinides
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan

    Kunio Shirato M.D., Ph.D. (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Tokyo

About this paper

Cite this paper

Konstantinides, S. (2005). Thrombolytic Treatment of Acute Pulmonary Embolism: Toward the End of a Long-Lasting Debate?. In: Shirato, K. (eds) Venous Thromboembolism. Springer, Tokyo. https://doi.org/10.1007/4-431-27121-X_2

Download citation

  • DOI: https://doi.org/10.1007/4-431-27121-X_2

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-22080-0

  • Online ISBN: 978-4-431-27121-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation